-=Cassava Sciences (SAVA) : Alzheimer's drug trial results

 

Cassava Sciences announces results of an interim analysis from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease

• Patients' cognition improved 1.6 Points on ADAS-Cog11.
• Patients' behavior improved 1.3 Points on NPI.
• Improvements maintained at 6 months.
• Results support advancing simufilam into Phase 3 clinical program.